Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $399,300.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total transaction of $399,300.00. Following the sale, the insider now directly owns 1,034,015 shares in the company, valued at $13,762,739.65. This trade represents a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Day One Biopharmaceuticals Trading Down 0.5 %

Shares of Day One Biopharmaceuticals stock opened at $12.75 on Friday. Day One Biopharmaceuticals, Inc. has a twelve month low of $11.94 and a twelve month high of $18.07. The firm has a market capitalization of $1.29 billion, a PE ratio of -12.38 and a beta of -1.51. The firm’s 50-day moving average price is $14.19 and its 200 day moving average price is $14.04.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period in the previous year, the company earned ($0.54) EPS. On average, sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DAWN. Mirae Asset Global Investments Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after purchasing an additional 1,002 shares during the last quarter. Quest Partners LLC boosted its position in Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after acquiring an additional 7,668 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at about $113,000. Point72 DIFC Ltd acquired a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at about $124,000. Finally, Hsbc Holdings PLC acquired a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at about $163,000. 87.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.